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Abstract: Background: The purpose of the study was to evaluate secondary stroke prevention in
Poland and its association with sociodemographic factors, place of residence, and concomitant
cardiovascular risk factors. Material and methods: From all patients in LIPIDOGRAM2015 Study
(n = 13,724), 268 subjects had a history of ischaemic stroke and were included. Results: 165 subjects
(61.6%) used at least one preventive medication. Oral antiplatelet and anticoagulation agents were
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used by 116 (43.3%) and 70 (26.1%) patients, respectively. Only 157 (58.6%) participants used lipid-
lowering drugs, and 205 (76.5%) were treated with antihypertensive drugs. Coronary heart disease
(CHD) and dyslipidaemia were associated with antiplatelet treatment (p = 0.047 and p = 0.012,
respectively). A history of atrial fibrillation, CHD, and previous myocardial infarction correlated
with anticoagulant treatment (p = 0.001, p = 0.011, and p < 0.0001, respectively). Age, gender, time
from stroke onset, place of residence, and level of education were not associated with antiplatelet
or anticoagulant treatment. Only 31.7% of patients were engaged in regular physical activity, 62%
used appropriate diet, and 13.6% were current smokers. Conclusions: In Poland drugs and lifestyle
modification for secondary stroke prevention are not commonly adhered to. Educational programmes
for physicians and patients should be developed to improve application of effective secondary
prevention of stroke.
Keywords: secondary stroke prevention; oral anticoagulant drugs; oral antiplatelet drugs; primary
health care
1. Introduction
Stroke is the second most common cause of death and the leading cause of adult
disability in developed countries. According to data from the World Health Organiza-
tion (WHO), about 17 million people worldwide suffer a stroke every year and about
5.5 million die. In Poland, the incidence of stroke is about 90,000 per year, of which
85% are ischaemic [1–4]. A history of a previous stroke is an important risk factor for
subsequent cerebrovascular events. The risk of recurrent stroke is 10–12% in the first
year and 5–8% in each subsequent one [5]. The frequency of recurrence depends on the
subtype of stroke and is highest in patients with embolic stroke of cardiac origin and in
cases with significant atherosclerotic narrowing of the carotid arteries [5,6]. According
to current guidelines, in all patients with atrial fibrillation (AF) and previous stroke (i.e.,
CHA2DS2VASc score ≥ 2 points), oral anticoagulants should be considered. Patients with
ischemic stroke who do not have AF should be treated with antiplatelets [7,8]. Secondary
stroke prevention includes also lifestyle modification (regular physical activity, proper diet,
body mass reduction, smoking cessation, and reducing alcohol intake), and elimination or
reduction of risk factors responsible for the first stroke (in particular guideline-specified
treatment of hypertension, dyslipidaemia and diabetes) [9–13].
Little is known about the application of secondary stroke prevention among Polish
patients, with the vast majority of former studies concerning the elderly [14–16]. Therefore,
the purpose of this study was to evaluate the use of oral antiplatelet (OAP) and antico-
agulant (OAC) drugs as secondary stroke prevention among people in Poland by using
primary care patients from the LIPIDOGRAM 2015 study. We also evaluated the association
of secondary stroke prevention with sociodemographic factors, place of residence, and
concomitant cardiovascular (CV) risk factors. In addition, we assessed secondary stroke
prevention in terms of lifestyle modification and elimination of other CV risk factors.
2. Materials and Methods
The LIPIDOGRAM2015 study—a nationwide observational, cross-sectional study of
cardiovascular health in primary care in Poland—was design to estimate the prevalence
of risk factors of atherosclerotic cardiovascular disease, frequency of cardiovascular and
related disorders, and their treatment in the primary care setting of Poland. The acronym
LIPIDOGRAM was constructed of two words: LIPID (lipid analysis—the main objective of
the study) and GRAM (the word comes from Greek and means “what is written”). A report
of the study was prepared in accordance with the STROBE Guidelines and a checklist is
presented as a Supplementary Materials.
From all patients included in the LIPIDOGRAM 2015 cohort study (n = 13,724),
268 subjects had a history of ischaemic stroke (documented discharge from the stroke
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unit) and they were chosen for this analysis. Patients with history of transient ischaemic
attack (TIA) were not included. Study design and rationale of The LIPIDOGRAM2015 and
LIPIDOGEN2015 study—a nationwide study of cardiovascular health in primary care in
Poland were described previously [17]. In brief, the study included 438 randomly selected
primary care physicians in 398 practices from 16 voivodeships (major administrative
regions in Poland). Each of them recruited at least 30 consecutive individuals >18 years old,
who were under the care of a physician–investigator and sought care for any medical reason
in the 4th quarter of 2015, or 1st and 2nd quarter of 2016. All patients were of Caucasian
Polish ethnicity. The main exclusion criteria were dementia and/or psychiatric disease.
To minimize potential sources of bias, each investigator–physician received individual
training related to the testing procedure and methodology. During the data collection
period, consultations with the main investor were also possible.
For each patient recruited for the study we completed a validated questionnaire in-
cluding demographic data (age, sex, place of residence, and level of education), history and
treatment of chronic cardiovascular diseases (CVD) (ischaemic and haemorrhagic stroke,
hypertension, coronary heart disease (CHD), myocardial infarction (MI), AF, diabetes mel-
litus (DM), dyslipidaemia, familial hypercholesterolaemia, chronic kidney disease (CKD)),
data on lifestyle (diet, physical activity, smoking status, alcohol intake), and CVD family
history [17–19]. Place of residence (i.e., habitual residence at the time of examination) was
classified as rural or urban. People were considered as rural residents when they were
living in a settlement unit with concentrated or dispersed buildings along with existing
agricultural functions or related service or tourist functions, without municipal rights or the
status of a city. Whereas people were regarded as urban residents when they were living
in a settlement unit with a predominance of compact development and non-agricultural
functions, having municipal rights or the status of a city granted in the manner specified by
the relevant act (Act on official names of places and physiographic objects, 29 August 2003,
Poland). The physicians completed questionnaires based on the patient interview and data
from medical records. The proper, antiatherogenic diet was defined as a Mediterranean-like
diet rich in fruits, vegetables, including legumes, fibre, polyunsaturated fatty acids, nuts,
and fish, with exclusion or limitation of simple sugars, red meat, dairy products, and
saturated fatty acids. Regular physical activity was defined as 30–60 min of moderate
activity for ≥5 days per week. Alcohol consumption was classified as none, moderate (up
to ≤100 g/week or ≤15 g/day), or high (>100 g/week or >15 g/day), and smoking status
as never, current, or in the past. To avoid missing data, only essential information was
collected. In this way, efforts were made to minimize the burden on doctors and patients.
There was also an effort to focus on routinely collected data.
For all recruited patients, anthropometric measurements were recorded (height, body
weight, waist circumference, and hip circumference). BMI (body mass index) was calculated
based on the height measurements in metres and body mass measurements in kilograms
(kg/m2). The WHR (waist hip ratio) was calculated as the ratio of the waist circumference
to the hip circumference. From all enrolled patients, serum samples were obtained after
at least 12 h of fasting to obtain fasting glucose, glycosylated haemoglobin (HbA1C), and
lipid profile. On the same day, measurements of blood pressure (BP) and heart rate (HR)
were performed.
The collected blood samples were transferred in cooled containers to a central lab-
oratory (Silesian Analytical Laboratories in Katowice, Poland). Measurements of total
cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and
low-density lipoprotein cholesterol (LDL-C) were performed and carried out using Siemens
Advia 1800 analyser and Siemens reagents (Munich, Germany). Fasting glycaemia was
measured using Bionime glucometers (Taichung City, Taiwan) and Rightest strip tests
(Taichung City, Taiwan). HbA1c was assessed using high-performance liquid chromatogra-
phy (HPLC) performed by Variant II Turbo (Bio-Rad, Hercules, CA, USA).
All individuals signed an informed consent form to participate in the study and gave
their permission to use anonymous questionnaire data and the results of their laboratory
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tests. The LIPIDOGRAM2015 Study was approved by the Bioethical Commission of the
Chamber of Physicians on 2 December 2015 (No. K.B.Cz.-0018/2015).
Statistical Analyses
Analyses were performed using SAS software, version 9.4 (SAS Institute Inc., Cary,
NC, USA). The quantitative data were presented using the mean and the standard de-
viation or median and interquartile range for normally and non-normally distributed
variables, respectively. The normality assumption was tested with the use of Shapiro–Wilk
test. The quantitative variables were compared with the Student’s t-test and Wilcoxon–
Mann–Whitney test as appropriate. Qualitative data were expressed as frequencies and
percentages, and the significance of between group differences was calculated by means of
the χ2 test. To assess the trend of stroke prevention according to the level of education the
Cochrane-Armitage test for trend was used. Odds ratios (OR’s) with 95% confidence inter-
vals (95% CI’s) were calculated by univariable logistic regression to assess the association
of different factors with applied agents.
3. Results
Among all the LIPIDOGRAM2015 Study participants (n = 13,724), 268 (2%) subjects,
141 women and 127 men, had a history of an ischaemic stroke and they were included
in this analysis. Characteristics of the study group are presented in Table 1. The mean
age of participants was 67.7 ± 9.4 years, similar for both men and women (66.6 ± 8.3 vs.
68.7 ± 10.2 years p = 0.061, respectively). The frequencies of concomitant cardiovascular
risk factors in the study group are summarized in Table 2.
Table 1. Characteristics of the study group (n = 268). Data presented as the number (n) and percentage
(%) value or mean and standard deviation (SD).















Data presented as mean ± SD
Age (mean ± SD), years 68 ± 9
BMI, kg/m2 29.5 ± 4.9
WHR 0.98 ± 0.1
Duration from acute stroke, years 6.6 ± 5.6
SBP, mmHg 138.2 ± 18.7
DBP, mmHg 81 ± 10.6
HbA1C, % 6.2 ± 1.14
TC, mg/dl 191.6 ± 53.8
HDL-C, mg/dl 51 ± 15.5
TG, mg/dl 151 ± 91.6
LDL-C, mg/dl 119.6 ± 47.4
J. Clin. Med. 2021, 10, 4472 5 of 14
Table 1. Cont.
Characteristics Patients with ISn = 268
Fasting glucose, mg/dl 115 ± 37.55
HR, bpm 74 ± 10
IS—ischaemic stroke; BMI—body mass index; WHR—waist hip ratio; SBP—systolic blood pressure;
DBP—diastolic blood pressure; HbA1C—glycosylated haemoglobin; TC—total cholesterol; HDL-C—high-
density lipoprotein cholesterol; LDL-C—low-density lipoprotein cholesterol; TG—triglycerides; HR—heart rate;
bpm—beats per minute; SD—standard deviation.
Table 2. Lifestyle and cardiovascular risk factors in the study group (n = 268). Data presented as the
number (n) and percentage (%) value.
Risk Factor n (%)
History of HS 5 (1.9%)
CHD 111 (41.4%)
Previous myocardial infarction 49 (18.3%)
History of AF 55 (20.5%)
Dyslipidaemia 186 (69.4%)




Overweight and/or obesity (BMI > 25 kg/m2) 222 (82.8%)
Smoking
current 36 (13.4%)






Regular physical activity 85 (31.7%)
Use of antiatherogenic diet 166 (62%)
HS—haemorrhagic stroke; CHD—coronary heart disease; AF—atrial fibrillation; DM—diabetes mellitus;
HT—hypertension; CKD—chronic kidney disease; BMI—body mass index.
Among the study group, only 165 subjects (61.6%) used at least one drug as part of a
secondary prevention regimen. Antiplatelet agents were regularly used by 116 patients
(43.3%), and oral anticoagulants by 70 subjects (26.1%). Antiplatelet and anticoagulant
therapy was simultaneously used by 21 patients (7.8%) (Table 3). A total of 103 subjects
(38.4%) were not being treated with antiplatelet agents or anticoagulants. Among partici-
pants with AF (n = 55; 20.5%), 35 (63.6%) used anticoagulants: 19 participants (54.3%) were
receiving vitamin K antagonists (VKAs) and 16 participants (45.7%) received non-vitamin K
antagonist oral anticoagulants (NOACs).
We also evaluated frequency of cardiovascular risk factor modification: 157 subjects
(58.6%) used hypolipidaemic drugs (statin and/or fibrate and/or ezetimibe), 205 (76.5%)
were treated with antihypertensive drugs, and 82 (30.6%) received antiglycaemic medica-
tions (Table 3). The median and interquartile range of systolic (SBP) and diastolic BPs (DBP)
in patients on antihypertensive therapy (n = 205) were 140 mmHg (130– 150) and 80 mmHg
(75–90), respectively, and were not significantly different from SBP (p = 0.910) and DBP
(p = 0.797) in patients without antihypertensive therapy (n = 7): 140 mmHg (120–150) and
80 mmHg (70–89), respectively.
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Table 3. Frequency of use of particular medications in the study group (n = 268).




















FDCs for dyslipidaemia 4 (1.5%)
Antidiabetics 82 (30.6%)
Antihypertensive drugs 205 (76.5%)





FDCs for hypertension 39 (14.6%)
Other antihypertensive drugs 31 (11.6%)
ASA—acetylsalicylic acid; NOAC—non-vitamin K antagonist oral anticoagulants; ACE—angiotensin convert-
ing enzyme; BBs—beta-blockers; CCBs—calcium channel blockers; ARBs—angiotensin II receptor blockers;
FDCs—fixed dose combination pills.
Patients taking lipid-lowering drugs had significant lower values of TC and LDL than
subjects without such therapy (TC: 177.7 mg/dl (149.7–202.2) vs. 212.4 mg/dl (192.6–241.1),
p < 0.001; LDL: 104 mg/dl (79–132) vs. 154 mg/dl (129–176), p < 0.001), whereas there
were no statistically significant differences in HDL and TG (HDL: 49.0 mg/dl (38.6–60.0) vs.
45.8 mg/dl (42.3–57.5), p = 0.896; TG: 121.4 mg/dl (97.6–187.9) vs. 127.0 mg/dl (95.2–187.5),
p = 0.669). Patients with DM using antiglycaemic medications had similar fasting glucose
to those without such treatment (122 mg/dl (110–158) vs. 125 mg/dl (118–134), p = 0.892).
Fasting glucose in patients without diagnosed DM was 100 mg/dl (91–109). HbA1C in
patients with DM was 7.1% (6.2–7.7) and in patients without DM it was 5.7% (5.4–5.9),
p < 0.001 (the data were presented as median and interquartile range).
The percentage of women after stroke using antiplatelet agents and/or anticoagulants
(58.9%; n = 83) was similar as the corresponding percentage of men after stroke (64.6%;
n = 82) (p = 0.338). The age of the respondents did not affect the prevalence of secondary
stroke prevention; mean age of participants using antiplatelet agents and/or anticoagulants
was similar to the age of participants without pharmacological stroke prevention (68.2 ± 9.6
and 66.8 ± 8.9 years, respectively, p = 0.206). Most of the study group lived in urban
areas (54.1%; n = 145). There were no differences in using antiplatelet agents and/or
anticoagulants between urban (62.8%; n = 91) and rural (60.2%; n = 74) residents (p = 0.663).
No correlation was found between the frequency of use of antiplatelet agents and/or
anticoagulants and the level of education (the Cochran–Armitage test for trend: p = 0.573).
Among all of the cardiovascular risk factors, CHD and dyslipidaemia were signifi-
cantly associated with antiplatelet drug treatment (p = 0.047 and p = 0.012, respectively),
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and AF history, CHD, and previous MI with anticoagulant treatment (p = 0.001, p = 0.011,
and p < 0.0001, respectively), see Table 4. The associations of different factors with antihy-
pertensive, hypolipidaemic, and antiglycaemic treatment are summarized in Table 5.
Table 4. Association of different factors with antiplatelets and/or anticoagulant treatment (n = 268).





























































































































HS—haemorrhagic stroke; CHD—coronary heart disease; AF—atrial fibrillation; DM—diabetes mellitus;
HT—hypertension; CKD—chronic kidney disease; BMI—body mass index; OR-odds ratio; CI-confidence interval.
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HS 0.45 (0.07–2.77) 0.392 1.06 (0.17–6.46) 0.948 3.49 (0.57–21.32) 0.175
CKD 1.73 (0.37–8.02) 0.484 1.63 (0.49–5.42) 0.428 1.01 (0.30–3.37) 0.989
CHD 2.82 (1.48–5.35) 0.002 1.56 (0.95–2.58) 0.080 1.78(1.05–3.01) 0.031
Previous myocardial infarction 2.06 (0.88–4.85) 0.098 1.14 (0.61–2.16) 0.678 2.67 (1.41–5.03) 0.003
AF 1.74 (0.80–3.78) 0.165 0.81 (0.45–1.48) 0.496 1.54 (0.83–2.86) 0.173
Dyslipidaemia 2.68 (1.49–4.81) 0.001 - - 1.42 (0.79–2.54) 0.241
Familial hypercholesterolaemia 2.192 (0.265–18.161) 0.467 - - 1.38 (0.32–5.89) 0.668
DM 3.19 (1.53–6.63) 0.002 1.54 (0.91–2.62) 0.111 - -
HT - - 2.98 (1.62–5.49) <0.001 5.82 (2.23–15.20) <0.001
Overweight/obesity BMI > 25 3.60 (1.84–7.04) <0.001 1.52 (0.81–2.88) 0.196 4.35 (1.65–11.47) 0.003
Current smoking 1.318 (0.548–3.173) 0.538 1.129 (0.550–2.317) 0.741 0.61 (0.27–1.40) 0.245
Age > 70 years 1.13 (0.62–2.05) 0.688 0.641 (0.386–1.064) 0.085 1.56 (0.92–2.67) 0.101
Male gender 1.17 (0.66–2.06) 0.593 0.762 (0.468–1.241) 0.275 1.16 (0.69–1.96) 0.569
Secondary/higher education 0.76 (0.43–1.35) 0.352 1.150 (0.703–1.883) 0.578 0.70 (0.41–1.20) 0.192
Urban residence 1.01 (0.57–1.775) 0.980 1.003 (0.616–1.634) 0.989 1.12 (0.67–1.89) 0.664
Regular physical activity 0.99 (0.54–1.83) 0.995 0.713 (0.424–1.199) 0.202 0.92 (0.53–1.62) 0.774
Use of antiatherogenic diet 0.77 (0.42–1.39) 0.378 0.808 (0.488–1.337) 0.407 0.45 (0.27–0.77) 0.004
Duration from stroke >1 year 1.37 (0.70–2.71) 0.359 1.106 (0.60–2.03) 0.744 1.15 (0.59–2.23) 0.686
HS—haemorrhagic stroke; CHD—coronary heart disease; AF—atrial fibrillation; DM—diabetes mellitus; HT—hypertension; CKD—chronic kidney disease; BMI—body mass index; OR-odds ratio; CI-confidence interval.
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4. Discussion
Based on this analysis of the LIPIDOGRAM2015 Study, we demonstrate that approxi-
mately 60% of examined patients with a history of a previous stroke applied anticoagulants
or antiplatelets as secondary pharmacological prevention. Moreover, the patients used
vitamin K antagonists more often than NOAC, and acetylsalicylic acid (ASA) was the most
commonly used antiplatelet drug.
This percentage is similar to that which had been described in our previous study
concerning respondents (aged 65 years and older) from the PolSenior project, carried
out between April 2008 and April 2012 [15]. However, the types of medication used in
secondary stroke prevention has changed. Today, many more patients are taking oral
anticoagulants (26.1% vs. 5.8% previously), including NOACs, which accounts for nearly
half of all OACs prescribed. Almost 65% of included patients after stroke with AF history
used anticoagulants, and this percentage was much higher than in our previous study
(20%) [14,15]. This still demonstrates a large gap in care and a critical need for widespread
educational programs both for physicians and patients in order to improve the secondary
prevention of ischemic stroke in Poland.
Among antiplatelet agents, ASA is the most frequently used drug in Poland, similarly
to other countries [14]. The second most frequently used antiplatelet drug was clopidogrel,
and here the situation has changed (previously ticlopidine was used more often) [14,15].
Dipyridamole was not at all used by our study group, similarly to that observed almost
ten years ago. This drug is recommended in combination with ASA as a very effective
agent for secondary stroke prevention [20–23]. Unfortunately, it is not dispensed in Polish
pharmacies. Dipyridamole is widely used in other European countries. For instance, in
Sweden it is prescribed in more than 10% of people discharged from the hospital after an
ischaemic stroke [20].
Among VKAs, acenocoumarol is still the most widely used drug in Poland, which
is in contrast to the United States and Western Europe, where warfarin is much more
popular [14,15]. Similar to our previous paper, we found no association between use
of antiplatelet agents and/or anticoagulants and age, sex, place of residence, or level of
education [15].
Secondary stroke prevention includes not only pharmacological treatment but also
modification of lifestyle and other cardiovascular risk factors. Hypertension is a major risk
factor for ischemic stroke, and its treatment can significantly reduce the risk of recurrent
ischemic stroke [23,24]. The current guidelines recommend starting antihypertensive
therapy in patients with SBP > 140 mmHg and/or DBP > 90 mmHg [23]. Thiazide diuretics
alone or in combination with an angiotensin-converting enzyme inhibitor (ACEI) should be
used in patients after stroke as a first-line treatment [23–25]. In our study, antihypertensive
drugs were taken by 76.5% of respondents; there were mostly diuretics (37.7%) and ACE
inhibitors (36.9%). However, this therapy was not always effective; the median SBP and
DBP in patients on antihypertensive therapy was 140 mmHg and 80 mmHg, respectively.
DM is a major risk factor for ischemic stroke and an increased HbA1c level is associated
with increased stroke risk in people with and without DM [26]. In the study group, the
control of diabetes was suboptimal. The average fasting glucose concentration in patients
with diabetes was about 120 mg/dl and HbA1C was 7.1%, which are higher than the
recommended levels in recent guidelines [23].
High dose, high intensity statin therapy should be considered in all patients after an
ischaemic stroke (based on very high cardiovascular risk). Adjuvant therapy with ezetimibe
or fenofibrate may also be indicated [27–30]. Statins were taken by only approximately 60%
of participants, but the average LDL concentration was still elevated (mean 104 mg/dl),
although not as high as in people not treated with lipid lowering drugs (154 mg/dl). It is
worth noting that in this study group of patients, the frequency of heterozygous familial
hypercholesterolaemia was much more frequent (3%) than in the general population
(0.2–0.5%) (Table 4).
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Although there are no clear recommendations concerning weight reduction in obese
patients after stroke, obesity is associated with other stroke risk factors such as hypertension,
diabetes, and dyslipidaemia [21,22]. The average BMI in the study group was nearly
30 kg/m2 and more than 80% of respondents were overweight or obese. Regular physical
activity is a known factor modifying other CV risk factors; it reduces blood pressure,
lowers serum levels of atherogenic lipoproteins and glucose, helps in maintaining proper
body weight; it also reduces the risk of recurrent stroke itself [25]. In this study, only one
third of stroke patients were engaged in regular physical activity, as they admitted in the
questionnaire. Smoking increases the risk of cerebrovascular incident 2–4 fold, so stroke
survivors should be advised to stop smoking [9]. The percentage of current smokers was
13.6% in our study. In addition, 1.5% of respondents admitted that they consume high
doses of alcohol. Another important lifestyle factor is an appropriate low-fat diet. Some
clinical trials revealed the benefits of use of the Mediterranean diet or DASH (Dietary
Approach to Stop Hypertension) diet in reducing cardiovascular risk, including stroke
risk [31–33]. In our study, 62% of the respondents tried to use an appropriate diet.
Limitations
It was surprising for us that about 40% of people after stroke did not admit antithrom-
botic and/or hypolipidemic drugs. Secondary prevention—both pharmacological and
lifestyle modification—should be ordered at discharge from stroke unit and then continued
ambulatorily by neurologists and/or primary care physicians. The reasons for discontin-
uing therapy could not be established from available data. One of reasons could be long
time from the stroke (6.6 ± 5.6 years) and patients’ non-compliance.
The study group was relatively small but representative for the primary health care
and the whole country (patients were recruited from every voivodeship). However, the
average age of the respondents was about 5 years lower than the average age of patients
hospitalized in Poland due to a first stroke [34]. The study did not include the most disabled
patients who stayed at home and were not able to consult a general practitioner. Evaluation
of smoking habits and alcohol consumption by questionnaire has limited validity. We
analysed the association of different factors with used medications, including antiplatelets,
anticoagulants, hypolipidaemic drugs, antidiabetics, and antihypertensive drugs, but it
should be emphasized that this relationship cannot show a causal relationship due to the
characteristic of cross-sectional study.
5. Conclusions
Poland therapeutic drugs and lifestyle modification for secondary stroke prevention
are not commonly adhered to. Educational programmes both for physicians and patients
should be developed to improve application of effective secondary prevention of stroke.
Procedures of patients’ adherence monitoring should be implemented.
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Brzostek J., Brzuchacz M., Budzyńska M., Bulzacka-Fugiel I., Bulzak J., Bunikowski K., Cebulska
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Petlic-Marendziak A., Piasecka T., Piaścińska E., Piktel A., Pilarska-Igielska A., Piotrkowska A.,
J. Clin. Med. 2021, 10, 4472 12 of 14
Piwowar-Klag K., Planer M., Plewa J., Płatkiewicz P., Płonczyńska B., Podgórska A., Polewska M.,
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Bywalec K., Tomiak E., Topczewski S., Trawińska A., Trela-Mucha L., Trojanowski D., Trzaskowska
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Bartman, W.; Więcek, A. Secondary prevention of stroke in elderly people in Poland—Results of PolSenior study. Neurol. Neurochir.
Pol. 2014, 48, 85–90. [CrossRef] [PubMed]
16. Łabuz-Roszak, B.; Skrzypek, M.; Machowska-Majchrzak, A.; Mossakowska, M.; Chudek, J.; Więcek, A.; Pierzchała, K.; Łącka-
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19. Jóźwiak, J.J.; Studziński, K.; Tomasik, T.; Windak, A.; Mastej, M.; Catapano, A.L.; Kausik, K.R.; Mikhailidis, D.P.; Toth, P.P.; on
behalf of the LIPIDOGRAM2015 and LIPIDOGRAM2015 Investigators; et al. The prevalence of cardiovascular risk factors and
cardiovascular disease among primary care patients in Poland: Results from the LIPIDOGRAM2015 study. Atherosclerosis Supp
2020, 42, e15–e24. [CrossRef]
20. Glader, E.L.; Sjolander, M.; Eriksson, M.; Lundberg, M. Persistent use of secondary preventive drugs declines rapidly during the
first 2 years after stroke. Stroke 2010, 41, 397–401. [CrossRef] [PubMed]
21. Asberg, S.; Henriksson, K.M.; Farahmand, B. Ischemic stroke and secondary prevention in clinical practice. Stroke 2010, 41,
1338–1342. [CrossRef] [PubMed]
22. Gao, R.; Li, X. Risk assessment and aspirin use in Asian and Western populations. Vasc. Health Risk Manag. 2010, 6, 943–956.
[PubMed]
23. Kernan, W.N.; Ovbiagele, B.; Black, H.R.; Bravata, D.M.; Chimowitz, M.I.; Ezekowitz, M.D.; Fang, M.C.; Fisher, M.; Furie, K.L.;
Heck, D.V.; et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline
for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014, 45, 2160–2236.
[CrossRef] [PubMed]
24. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105
individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358, 1033–1041.
25. Oza, R.; Rundell, K.; Garcellano, M. Recurrent Ischemic Stroke: Strategies for Prevention. Am. Fam. Physician. 2017, 96, 436–440.
[PubMed]
26. Mitsios, J.P.; Ekinci, E.I.; Mitsios, G.P.; Churilov, L.; Thijs, V. Relationship between glycated hemoglobin and stroke risk: A
systematic review and meta-analysis. J. Am. Heart Assoc. 2018, 7, e007858. [CrossRef] [PubMed]
27. Solnica, B.; Sygitowicz, G.; Sitkiewicz, D.; Cybulska, B.; Jóźwiak, J.; Odrowąż-Sypniewska, G.; Banach, M. 2020 Guidelines of
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